As an internal medicine physician at StayWell Health Center in Waterbury, Connecticut, Dr. Rex Mahnensmith draws on a background that includes fellowship training in nephrology. Also a former chief of nephrology at Miriam Hospital, Dr. Rex Mahnensmith continues to focus on the needs of patients with chronic kidney disease.
On June 12, 2017, pharmaceutical companies Eli Lilly and Boehringer Ingelheim (BI) officially announced their intent to investigate their existing product Jardiance as a potential treatment for chronic kidney disease. Jardiance is currently in use as a sodium-glucose co-transporter-2 (SGLT2) inhibitor, used to lower blood glucose levels in patients with type 2 diabetes.
The announcement follows data from a 2015 cardiovascular outcomes trial that indicated the potential of Jardiance to reduce the risk of cardiovascular fatalities by 38 percent. In 2016, Eli Lilly and BI released a new analysis of the same study that showed Jardiance's ability to reduce two key measures of kidney problems.
The drug effectively reduced the progression of microalbuminuria, defined as excessively high levels of the protein albumin in the patient's urine. It also reduced doubling of the waste product creatinine, a process indicative of kidney decline, by approximately 44 percent. Furthermore, and perhaps most notably, the drug reduced the incidence of dialysis and other renal replacement therapies by 55 percent.
The June 12 announcement came with additional data to support the potential of Jardiance to slow the decline of kidney function, even in patients at high risk of kidney disease. Following this evidence, Eli Lilly and BI will start a large clinical outcomes trial that will involve approximately 5,000 patients with chronic kidney disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.